Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;31(4):737-47.
doi: 10.1007/s11011-016-9824-z. Epub 2016 Apr 13.

TDO as a therapeutic target in brain diseases

Affiliations
Review

TDO as a therapeutic target in brain diseases

Cheng-Peng Yu et al. Metab Brain Dis. 2016 Aug.

Abstract

Tryptophan-2, 3-dioxygenase (TDO) is a heme-containing protein catalyzing the first reaction in the kynurenine pathway, which incorporates oxygen into the indole moiety of tryptophan and catalyzes it into kynurenine (KYN). The activation of TDO results in the depletion of tryptophan and the accumulation of kynurenine and its metabolites. These metabolites can affect the function of neurons and inhibit the proliferation of T cells. Increasing evidence demonstrates that TDO is a potential therapeutic target in the treatment of brain diseases as well as in the antitumor and transplant fields. Despite its growing popularity, there are few reviews only focusing on TDO. Hence, we herein review TDO by providing a comprehensive overview of TDO, including its biological functions as well as the evolution, structure and catalytic process of TDO. Additionally, this review will focus on the role of TDO in the pathology of three groups of brain diseases: Schizophrenia, Alzheimer's disease (AD) and Glioma. Finally, we will also provide an opinion regarding the future developmental directions of TDO in brain diseases, especially whether TDO has a potential role in other brain diseases as well as the development and applications of TDO inhibitors as treatments.

Keywords: Alzheimer’s disease; Glioma; Schizophrenia; TDO; Tryptophan metabolism.

PubMed Disclaimer

References

    1. J Clin Neurosci. 2009 Oct;16(10 ):1283-6 - PubMed
    1. Epilepsy Res. 2011 May;94(3):206-12 - PubMed
    1. J Neurochem. 2005 May;93(3):762-5 - PubMed
    1. J Neurol Sci. 1995 May;130(1):39-47 - PubMed
    1. Arch Gen Psychiatry. 1965 Dec;13(6):483-94 - PubMed

Publication types

Substances

LinkOut - more resources